Morgan Keegan Reiterates Outperform on Edwards Lifesciences

Morgan Keegan is out with its report today on Edwards Lifesciences EW, reiterating Outperform. In its report, Morgan Keegan writes, "We are reiterating our Outperform rating for Edwards Lifesciences after reevaluating its percutaneous valve market opportunity and the risk to the number of patients that may be reimbursed in the U.S because of higher complication rates than experienced in aortic valve replacements in the Partner IDE trial." Morgan Keegan maintains a $97 PT on EW. Shares of EW closed Friday at $67.73, up 0.79% from Thursday's close.